Preference to Targeted Therapies and Patient Centric Approaches Drive Transformations in Oncology Drug Delivery Market

Published: 30 Jun 2017

Cancer is the second largest cause of death and is expected to surpass cardiovascular diseases as the leading cause of deaths over the next few years. According to NIH estimates, medical expenditure for cancer in the United States is expected to cross $150 billion by 2020, thereby putting even higher cost pressure on already overburdened US healthcare economy. Traditionally, surgery and radiotherapy have been the primary treatment, with anti-cancer drugs largely being used in metastatic cancers. Although chemotherapy has been successfully used for inhibiting cell growth over the last couple of decades, side-effects of chemotherapy have forced researchers to look for some alternative medications for all types of cancer. With medications and therapies, the challenge with drug developers has been to effectively administer the drugs at the disease site in human body. To overcome this challenge, earlier while a majority of drugs were administered through injectable medium, the focus of drug manufacturers has currently shifted toward developing effective needle-free delivery systems, as driven by their patient-centric health care approach.

Sign in to read the rest of this article

Not signed up? Register now Forgot your password?

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..